Key result
High-dose fenofibrate over one week caused skeletal muscle atrophy via enhancement of FoxO1, and combination treatment with lovastatin further increased FoxO1 protein levels.
Why the study?
Fibrates and statins are linked to muscle atrophy and rhabdomyolysis, prompting investigation into whether fenofibrate alone or with lovastatin affects FoxO1 and its target genes in skeletal muscle.
Does fenofibrate alone or in combination with lovastatin induce skeletal muscle atrophy and increase FoxO1 expression in mice?
Does fenofibrate alone or in combination with lovastatin induce skeletal muscle atrophy and increase FoxO1 expression in mice?
High-dose fenofibrate induces skeletal muscle atrophy via PPARα-dependent upregulation of FoxO1 and its targets, and combination with lovastatin further increases FoxO1 protein levels, providing mechanistic insight into fibrate/statin-induced myopathy.
Answers are grounded in this paper and cite their sources.
Should not yet change fibrate-statin prescribing; leaves open FoxO1 translation to human myopathy risk.
Fibrates and statins have been widely used to reduce triglyceride and cholesterol levels, respectively. Besides its lipid-lowering effect, the side effect of muscle atrophy after fibrate administration to humans has been demonstrated in some studies. Combination therapy with fibrates and statins also increases the risk of rhabdomyolysis. FoxO1, a member of the FoxO forkhead type transcription factor family, is markedly upregulated in skeletal muscle in energy-deprived states and induces muscle atrophy via the expression of E3-ubiquitine ligases. In this study, we investigated the changes in FoxO1 and its targets in murine skeletal muscle with fenofibrate treatment. High doses of fenofibrate (greater than 0.5% (wt/wt)) over one week increased the expression of FoxO1 and its targets in the skeletal muscles of mice and decreased skeletal muscle weight. These fenofibrate-induced changes were diminished in the PPARα knockout mice. When the effect of combination treatment with fenofibrate and lovastatin was investigated, a significant increase in FoxO1 protein levels was observed despite the lack of deterioration of muscle atrophy. Collectively, our findings suggest that a high dose of fenofibrate over one week causes skeletal muscle atrophy via enhancement of FoxO1, and combination treatment with fenofibrate and lovastatin may further increase FoxO1 protein level.
No takes yet. Share an insight, caveat, or question.
Ajima et al. (2021) studied Skeletal muscle atrophy. Fenofibrate and Lovastatin vs. High-carbohydrate diet without drugs was evaluated on FoxO1 protein and mRNA expression and skeletal muscle weight (p=<0.05). High-dose fenofibrate over one week caused skeletal muscle atrophy via enhancement of FoxO1, and combination treatment with lovastatin further increased FoxO1 protein levels.
Synapse has enriched 10 related papers. Consider them for comparative context: